Plain-English translation of NCT07444398 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether a medication called vericiguat, when added to your regular heart failure medications, can help keep you out of the hospital and improve your health. You would receive either vericiguat at increasing doses (up to 10 mg daily) plus your standard treatment, or standard treatment alone. The study will follow you for 3 months to see how well the medication works.
Heart failure patients who come to the emergency department with worsening symptoms need better treatment options to prevent future hospitalizations and complications. This trial is examining whether this medication can fill that gap when added to the medications doctors already prescribe.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to either take the new medication along with your regular heart failure treatments, or to continue with your standard treatment alone. If you receive the new medication, you would start at a low dose and gradually increase it over time as your doctor monitors your blood pressure and symptoms. You would visit the clinic for check-ups every month for 3 months, where doctors would ask about any hospitalizations, side effects, or changes in how you're feeling.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
Pakistan